Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

February 26, 2026
At Pharmidex , we deliver industry-leading Discovery Bioanalysis services grounded in advanced LC-MS technologies to enhance drug discovery and preclinical research, supporting internal studies but also analyzing external samples also Our experienced bioanalytical team works across a wide range of therapeutic modalities, from small molecules and peptides, to oligonucleotides and complex biologics, providing robust, reliable and fit-for-purpose data to accelerate your program and strengthen decision-making during early development. We support both non-GLP and GLP/GCP workflows, method development, validation, and quantitative analysis that align with regulatory needs and industry expectations. Learn more about how our LC-MS capabilities can help you confidently advance your projects: 🔗 https://www.pharmidex.com/Discovery-Bioanalysis
February 24, 2026
Today we took a short pause from the science to enjoy some well-deserved donuts together in the office. At Pharmidex , we believe culture matters just as much as capability. Moments like this simple, informal, and inclusive are part of what keeps our team connected and motivated. As a preclinical CRO, we support over 400 clients each year from our UK laboratories, delivering high-quality in vivo and bioanalytical services to advance drug discovery programmes.  A small break. A strong team. Back to delivering great science. If we can support your next drug discovery project, do get in touch.
February 23, 2026
🧠 Did you know that Pharmidex offers specialist CNS preclinical services to accelerate neuroscience drug discovery? At Pharmidex, we provide expert in vivo and ex vivo neurochemistry and neurobehavioural capabilities to support the progression of CNS drug candidates across key readouts including PK, PD, target engagement and efficacy. Our CNS platform is designed to help you address the complex challenges of developing therapies for neurodegenerative and psychiatric disorders such as Alzheimer’s, Parkinson’s, schizophrenia and depression. From microdialysis and brain bioanalysis to blood–brain barrier assessment and sophisticated neurobehavioural models, we deliver actionable data to guide confident decision-making in your neuroscience programmes. Learn more about how Pharmidex can support your CNS research: 🔗 www.pharmidex.com/CNS
More Posts